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RACE AS A PROXY FOR DRUG RESPONSE: THE
DANGERS AND CHALLENGES OF
ETHNIC DRUGS
Rene Bowser*
INTRODUCTION
Considerable debate exists concerning the use of race in medical
research and in clinical practice. Race, according to some, is of little
or no biological significance and, therefore, should be of little or no
importance in making treatment decisions.1 Others insist that a pa-
tient's race can, and should, influence the doctor's thinking about pos-
sible diagnoses and cures.2
Pharmacogenomics has fueled the controversy.3 Physicians have
long known that individual patients respond differently to medications
even at the standard dose. Thus, prescribing drugs is an iterative pro-
cess in which physicians initially prescribe a standard dose or choice of
medication and then adjust in response to observed toxic or therapeu-
tic response. Having an a priori knowledge of a patient's drug re-
sponse is clearly beneficial.
Well-meaning scientists now suggest that race may serve as a proxy
for drug response. Numerous studies seem to indicate that patients of
different racial and ethnic groups metabolize drugs differently due to
differences in genetics. 4 Other scientists suggest that the observed ra-
* Associate Professor of Law, University of Illinois College of Law.
1. See Jay S. Kaufman & Richard S. Cooper, In Search of the Hypothesis, 110 PUB. HEALTH
REP. 662 (1995); Newton G. Osborne & Marvin D. Feit, The Use of Race in Medical Research,
267 JAMA 275 (1992); Robert S. Schwartz, Racial Profiling in Medical Research, 344 NEW ENG.
J. MED. 1392 (2001).
2. See, e.g., SALLY L. SATEL, PC, M.D.: How POLITICAL CORRECTNESS IS CORRUPTING
MEDICINE (2000). Current textbooks still say that knowing a patient's race helps the doctor
make an accurate diagnosis.
3. Pharmacogenomics refers to the study of how inherited genetic variations affect an individ-
ual's ability to respond to a drug and the use of that knowledge in drug discovery and develop-
ment. Race-specific drug therapy draws its rationale from the presumption that the frequencies
of genetic variants influencing the efficacy of a drug are substantially different among races.
Richard S. Cooper et al., Race and Genomics, 348 NEW ENG. J. MED. 1166 (2003).
4. See, e.g., Alastair JJ. Wood, Racial Differences in the Response to Drugs-Pointers to Ge-
netic Differences, 344 NEW ENG. J. MED. 1393 (2001).
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cial differences in drug metabolism are not sufficiently precise or sig-
nificant to make them clinically useful in guiding the choice of drugs.5
Despite tremendous gaps in scientific knowledge, corporations are
not waiting. The newest wave in pharmaceutical research and market-
ing is ethnic niche markets. BiDil, a heart drug for African Americans,
is currently being tested on six hundred African Americans at over
one hundred sites.6 The Food and Drug Administration (FDA) has
stated that it will approve the marketing of BiDil to African Ameri-
cans (and only to African Americans) if it confers a significant benefit
in slowing down the development of congestive heart failure in study
participants. 7 Press reports have uncritically reported BiDil as a
breakthrough in treating heart failure in African Americans.8 Other
drug companies are racing to find other candidate ethnic drugs.
The current search for racial differences to increase corporate profit
should give us pause. As Patricia King points out:
[A] significant aspect of the Tuskegee experiment's legacy is that in
a racist society that incorporates beliefs about the inherent inferi-
ority of African Americans in contrast with the superior status of
whites, any attention to the question of differences that may exist is
likely to be pursued in a manner that burdens rather than benefits
African Americans. 9
This Article suggests that African Americans are more likely to be
harmed than helped by the commercialization of presumed genetic
differences in drug response.
II. THE LIMITATIONS OF RACIAL AND ETHNIC DATA
Concepts of race and ethnicity have evolved over time but tend to
be nebulous and poorly defined in scientific research. 10 Typically, a
study participant's race or ethnicity is assessed on a questionnaire with
5. See, e.g., Cooper et al., supra note 3, at 1166; Constance Holden, Race and Medicine, 302
Sci. 594 (2003).
6. Press Release, NitroMed, NitroMed Receives FDA Letter on BiDil NDA, a Treatment for
Heart Failure in Blacks Patients (Mar. 8, 2001), available at http://www.nitromed.com/new-
sindex.html (last visited Apr. 16, 2004).
7. Id.
8. See, e.g., Victoria Griffith, FDA Backs Ethnically Targeted Drug, FIN. TIMES, Mar. 9, 2001,
at 13; Ellen Licking, This Heart Drug Is Designed for African Americans, Bus. WK., Mar. 26,
2001, at 71.
9. Patricia A. King, The Dangers of Difference, 22 HASTINGS CENTER REP. 35 (1992).
10. Scarlett S. Lin & Jennifer L. Kelsey, Use of Race and Ethnicity in Epidemiologic Research:
Concepts, Methodological Issues, and Suggestions for Research, 22 EPIDEMIOLOGIC REV. 187,189
(2000). The most contemporary and evidence-based position on race is that "it has become clear
that human populations are not unambiguous, clearly demarcated, biologically distinct groups."
Am. Anthropological Ass'n, American Anthropological Association Statement on "Race" (May
17, 1998), at http://www.aaanet.org/stmts/racepp.htm (last visited Apr. 16, 2004).
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one or two questions, such as "what race do you consider yourself?"
or "where did your ancestors come from?" Self-reporting is often sug-
gested as the optimal method of collecting racial and ethnic data.1
However, questions have been raised about the validity and reliability
of self-reported data.'2
Frequently, race is assessed by the perceptions of an interviewer.1 3
Concerns about the validity and reliability of these assignments have
also been raised. 14 As a general matter, the race and ethnicity assign-
ments are made according to the assumptions and biases of the ob-
server. Nonbiological factors like skin color, hair texture, surname,
language spoken, and neighborhood of residence are used to assign
individuals to mutually exclusive categories from which scientific re-
sults are obtained.' 5
In the United States, slavery cemented the importance of skin color.
The 1890 U.S. Census distinguished mulatto (half black and half
white) from quadro (one-fourth black) from octoroon (one-eighth
black). And there was the "one drop" rule. If you had one black
ancestor, you were black. The 2000 Census allowed people for the
first time to check one of six races including "some other race," which
produced sixty-three combinations. About 6.8 million individuals
(2.4% of the U.S. population) consider themselves multiracial.' 6
The Census changes also resulted in 800,000 respondents who said
that they were both black and white.17 Moreover, the Census Bureau
estimates that 75% of those who currently identify themselves as
11. See, e.g., Jay S. Kaufman, How Inconsistencies in Racial Classification Demystify the Race
Construct in Public Health Statistics, 10 EPIDEMIOLOGY 101 (1999).
12. In the clinical context, one's self-report of race ethnicity is less important than the percep-
tion of the health care professional, whose perception frequently determines the diagnosis and
treatment. Likewise, self-perception in clinical trials can either overstate or understate the ef-
fects of discrimination and racism, factors that confound the clinical response to treatment.
13. Judith B. Kaplan & Trude Bennett, Use of Race and Ethnicity in Biomedical Publication,
289 JAMA 2709, 2710 (2003).
14. Id. at 2710.
15. A 2002 study found a high rate of discord between race and ethnicity as self-perceived and
as recorded in clinical records for a large number of Veteran Administration patients; 70% of
those who selected American Indian or Alaska Native were inconsistently recorded in the
database, as were 14.1% of those who chose Spanish, Hispanic, or Latino, 13% of those who
chose Asian, 5% of those who chose black or African American, and 1.5% of those who chose
white. Ulrike Boemer et al., Self-Reported vs Administrative Race/Ethnicity Data and Study Re-
suits, 92 AM. J. PuB. HEALTH 1471 (2002).
16. U.S. CENSUS BUREAU, U.S. DEP'T OF COMMERCE, CENSUS 2000 PROFILE: RACE, COMBi-
NATIONS OF Two RACES AND NOT HISPANIC OR LATINO: 2000, available at http://factfinder.
census.gov/servlet/QTrable?_bm=y&-geo-id=01000US&-qr._name=DEC2000_SF1_UQTP4&
-dsname=DEC_2000SF1U&--lang=EN&-_sse=ON (last visited Apr. 16, 2004).
17. Id.
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black could also identify themselves as multiracial. 18 Consider the sit-
uation of Elyse Frazier, one of the participants in the BiDil clinical
trials. When asked if she would be interested in participating in the
study for African Americans, she was puzzled. Frazier's mother is
half black, half Cherokee Indian, while her father is half black, half
Blackfoot Indian. She was informed that she was eligible for the
study, despite her ambivalence. 19
Racial and ethnic identification can be complex and contextual.
The racial identification of American Indians illustrates how self-iden-
tification can change over time. The number of American Indians in-
creased 255% in thirty years (552,000 in 1960 to 1,959,000 in 1990).20
As Michael Omi points out, "[this] rate of increase is virtually impos-
sible demographically, but much of the increase is explained by
changes in racial self-identification. These changes are driven by shifts
in attitudes toward American Indians, a romanticization of the past
and tangible benefits tied to American Indian identification. 2 1
Viewed as a static and typological concept, race is inherently unable
to explain the complex and changing structure of human biological
variation.22 As with the 2000 Census, individuals will fail to fit neatly
into racial boxes. Moreover, as anthropologist Alan Goodman has
noted, "the placement of an individual into a given box says little
about his or her biology: the racial mean is meaningless. '23 Research
efforts that rely on ill-defined and crude measures of race will by ne-
cessity provide compromised answers.
III. RACE AND PHARMACOGENOMICS
The fundamental question is whether racial differences in drug re-
sponse do exist, and whether these differences can ever be useful for
guiding treatment. As described below, the existing evidence suggests
that race is a rather poor proxy for drug response.
First, race disappears when you look at the human genome. Studies
of nuclear DNA sequences make clear that what is called race reflects
just a few continuous traits determined by a tiny fraction of our
18. Lawrence Wright, One Drop of Blood, NEW YORKER, July 25, 1994, at 46, 48.
19. Ariana Eunjung Cha, Race Plays Role in New Drug Trials: Treatment by Genetic Origin,
Ethnicity Divides Medical Profession, WASH. POST, July 28, 2003, at Al.
20. Michael Omi, Racial Identity and the State: The Dilemmas of Classification, 15 LAW &
INEQ. 7 (1997).
21. Id. at 15.
22. See, e.g., Alan H. Goodman, Why Genes Don't Count (for Racial Differences in Health),
90 AM. J. PUB. HEALTH 1699 (2000).
23. Id.
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genes.2 4 In other words, what people consider racial differences com-
prise only 0.01% of the body's estimated 35,000 genes. This tiny per-
centage gives no indication of variation at other parts of our
genome. 25 Moreover, most geneticists concur that the bulk of genetic
variation (90% to 95%) occurs within, not among, continental popula-
tions.26 Thus, it is quite often the case that two persons from the same
part of the world who look superficially alike are less related to each
other genetically than two persons from other parts of the world who
may look different.2 7
Although it is obvious that many genetic diseases vary markedly
among populations, those conditions are generally rare. Tay-Sachs
disease, cystic fibrosis, and sickle cell trait, for example, are absent in
many populations but present in others. For these conditions, racial
groups are not the populations of interest. Persons of Jewish descent,
not "whites," share a risk of Tay-Sachs disease; Americans of North-
ern European descent are more likely than other Americans to de-
velop cystic fibrosis; and the sickle cell trait, thought to be an
"African" trait, is found in many populations in which malaria was
endemic, including the Mediterranean and Southern India.28
Further, in any common disease such as heart failure or cancer,
many genes are likely to be involved and each gene will have many
24. Svante P5ibo, The Human Genome and Our View of Ourselves, 291 Sci. 1219 (2001).
25. Id. at 1220.
26. Kelly Owens & Mary Clair King, Genomic Views of Human History, 286 Sci. 452 (1999).
Genetic studies often use social labels such as "Chinese," "Nigerian," and "African American,"
that conceal a great deal of biological variation. Even a more specific ethnic label such as "Yo-
ruba," which refers to a population of over ten million people distributed across a large multina-
tional region of West Africa, can mask significant intragroup variation. See Richard Cooper et
al., Heritability of Angiotensin-Converting Enzyme and Angiotensinogen: A Comparison of US
Blacks and Nigerians, 35 HYPERTENSION 1141 (2000).
27. Id. Alan R. Templeton observes that human races are not distinct lineages, and this is not
due to recent admixture; human races are not and never were pure. Instead, Templeton states
"[hiuman evolution and population structure have been and are characterized by many locally
differentiated populations coexisting at any time, but with sufficient genetic contact to make all
of humanity a single lineage sharing a common evolutionary fate." Alan R. Templeton, Human
Races; A Genetic and Evolutionary Perspective, 100 AM. ANTHROPOLOGIST 632-50 (1999).
28. See, e.g., Cooper et al., supra note 3, at 1167. See also Joseph L. Graves, THE EMPEROR'S
NEW CLOTHES: BIOLOGICAL THEORIES OF RACE AT THE MILLENNIUM (2001). Several indepen-
dent mutations in the (beta)-globin gene gave rise to different sickle hemoglobins in central and
west Africa. These mutations spread through the population because they protected against
malaria. They were dispersed in Greece, Saudia Arabia, Turkey, Iran, and elsewhere by migra-
tion and slavery. The frequency of the sickle cell trait (carrier status) among the African-Ameri-
can population is 8%. See Kangpu Xu et al., First Unaffected Pregnancy Using Preimplantation
Genetic Diagnosis for Sickle Cell Anemia, 281 JAMA 1701 (1999). In the United States, nearly
10% of patients with various sickling disorders identify themselves as non-African Americans.
See Darlene R. Powers, Sickle Cell Disease in Non-Black Persons, 271 JAMA 1885 (1994).
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variants. 29 As Richard Cooper points out: "All the current data indi-
cate that susceptibility alleles tend to be old, have moderate-to-small
effects, and are shared among many populations. '30
Drug response is also influenced by a host of factors, including
overall health, lifestyle, support system, education, and socioeconomic
status. All of these factors are difficult to control for and are likely to
be affected, at least in the United States, by a person's race. 31
To confirm that it makes more biological sense to consider drug-
metabolizing genes rather than skin color in drug choice, James Wil-
son, David Goldstein, and colleagues at University College London,
compared twenty-three markers for such genes among 354 people rep-
resenting eight classically defined races: white (Norwegian, Askenazi
Jews, Armenians), black (Bantu, Ethiopian, and Afro-Caribbean),
and Asian (Chinese and New Guinean). 32 Using a technique called
hierarchical cluster analysis, they found that the genetic markers form
four natural groupings that do not correspond to any of the appear-
ance-defined categories. 33 The results highlight what we already
know: there exists substantial genetic diversity of individuals, which
goes far beyond that which can be attributed to skin color or geo-
graphic origin.34
Howard L. McCleod, a professor of medicine at the Washington
School of Medicine in Missouri concludes: "There is no clear link be-
tween skin pigment and drug metabolism. Skin pigment is a lousy
surrogate for drug metabolism status or most any aspect of human
physiology."35
IV. RACIAL REPACKAGING-THE STORY OF BIDIL
Even though race has not been shown to be a strong proxy for drug
metabolism, a drug called BiDil is poised to become the first drug ever
approved by the FDA to treat heart failure in African Americans, and
only in African Americans. BiDil is a combination of two vasodila-
tors, hydralazine and isosorbide dinitratre (H/I). Vasodilators dilate
29. Cooper et al., supra note 3, at 1168.
30. Id.
31. Editorial, Genes, Drugs and Race, 29 NATURE GENETICS 239, 240 (2001).
32. James F. Wilson et al., Population Genetic Structure of Variable Drug Response, 29 NA-
TURE GENETICS 265 (2001).
33. Id. at 267.
34. In an editorial, the journal Nature Genetics advocated the use of the race-neutral approach
proposed by Wilson and others because it moves us closer to the ultimate goal of "individualized
therapy." See Genes, Drugs and Race, supra note 31, at 240.
35. Howard L. McCleod, Pharmacogenetics: More Than Skin Deep, 29 NATURE GENETICS 247
(2001).
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blood vessels and ease the strain put on the heart in pumping blood.
BiDil is thought to have an added benefit of improving levels of nitric
oxide in the blood, which is also thought to be of great benefit to
individuals suffering from heart failure.36
BiDil is an underused drug that has been around for decades; it
certainly did not begin as an ethnic drug. This brief review of BiDil's
origins demonstrates the centrality of commerce and the exploitation
of racial categories in the repackaging of BiDil as a wonder drug for
African Americans. 37
It all begins with the first Vasodilator Heart Failure Trial (V-HeFT
I). In this medical trial, which lasted from 1980 to 1985, cardiologists
found that the H/I (BiDil) combination appeared to have a beneficial
impact in reducing mortality from heart disease.38 The V-Heft I trial
was soon followed by another trial, V-HeFT II, which lasted from
1986 to 1991. This trial compared the efficacy of the H/I (BiDil drugs)
against the drug enalapril, an angiotensin-converting enzyme (ACE)
inhibitor. The second trial found that enalapril had a more beneficial
effect on mortality than the HI combination. 39  The results of the
second trial established ACE inhibitors as the front-line therapy for
heart failure.40 ACE inhibitors have not totally replaced H/I, how-
ever, because between 20% and 30% of congestive heart failure pa-
tients do not respond well to them. That is roughly 1.5 million
patients annually (including members of all racial groups), and current
guidelines still recommend the H/I combination for these patients.41
The V-HeFT investigators presented the H/I (BiDil drugs) as gener-
ally efficacious in the population at large, without regard to race. In
1987, Dr. Jay Cohn, one of the principal investigators in the V-HeFT
studies applied for and received a patent on the H/I drugs.42 In the
patent description, Cohn made no mention of race, asserting that H/I
36. Press Release, NitroMed, supra note 6.
37. For an excellent and comprehensive review of BiDil, see Jonathan Kahn, How a Drug
Becomes "Ethnic": Law, Commerce, and the Production of Racial Categories in Medicine, 4
YALE J. HEALTH POL. L. & ETHICS 101 (2004).
38. Jay N. Cohn et al., Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart
Failure: Results of a Veterans Administration Cooperative Study, 314 NEw ENG. J. MED. 1547
(1986).
39. Jay N. Cohn et al., A Comparison of Enalapril with Hydralazine-Isorbide Dinitrate in the
Treatment of Chronic Congestive Heart Failure, 325 NEW ENO. J. MED 303 (1991).
40. Id.
41. See, e.g., AM. COLL. OF CARDIOLOGY & AM. HEART Ass'N, ACC/AHA GUIDELINES FOR
THE EVALUATION AND MANAGEMENT OF CHRONIC HEART FAILURE IN THE ADULT 2001, avail-
able at http://www.americanheart.org/downloadable/heart/1013201138293HFGuidelineFinal.pdf
(last visited Apr. 14, 2004); C. Packer, Consensus Recommendations for the Management of
Chronic Heart Failure, 83 AM. J. CARDIOLOGY 1A, 25A (1999).
42. U.S. Patent No. 4,868,179 (issued Sept. 19, 1989).
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substantially and significantly reduces the incidence of mortality in
congestive heart patients. Clearly, he believed the BiDil drugs would
be used to treat all people suffering from heart failure.43
The H/I drugs are generic drugs. Cohn and others combined them
into a single pill for easy administration. By 1994, tests were con-
ducted to make sure that the pill form was just as effective as the
administration of the drugs separately. They were. Cohn and Medco,
which had acquired the intellectual property rights from Cohn, were
now ready to approach the FDA for the approval of BiDil for use in
the general population.44
In 1996, Medco submitted a new drug application (NDA) to the
FDA. Jay Cohn optimistically asserted at the time that the BiDil for-
mulation represented a very convenient dosage that, once approved
by the FDA, would lead to an increased usage of this therapy in the
general population.45 An industry report estimated a potential mar-
ket of up to sixty million dollars in annual sales for BiDil.46
In an unanticipated move, however, the FDA voted nine to three
against approving BiDil, even though extensive findings in peer re-
viewed journals supported Cohn's claim that the H/I combination sub-
stantially and significantly reduced the incidence of mortality in
congestive heart failure patients.47 The agency concluded that while
the drug had clinical significance, it failed to meet the biostatistical
criteria of probability and efficacy sufficient for the FDA to grant a
NDA. In particular, the FDA noted that data from the V-Heft studies
contained too many variables specified as endpoints for them to inter-
pret the data with biostatical certainty.4 The next day, Medco's stock
dropped by 25%. 4 9
To salvage the drug, the BiDil promoters repackaged it along racial
lines. Jay Cohn went back one more time to the V-HeFT data, this
time to analyze the differential effects of BiDil and enalapril by race.50
43. See Kahn, supra note 37, at 113.
44. Id.
45. Id. at 114.
46. Id. at 113-14.
47. Id. at 114-15. The American Heart Association, the American College of Cardiology, and
the World Health Organization had all included HI as a recommended therapy for patients who
did not tolerate ACE inhibitors. CTR. FOR DRUG EVALUATION & RES., FOOD & DRUG ADMIN.,
CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMM'N, 80TH MEETING (Feb. 27, 1997),
available at http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3264t2.pdf (last visited Apr. 16,
2004).
48. See Kahn, supra note 37, at 114.
49. Id.
50. Although the V-HeFT investigators had been tracking data by race from the outset, they
had never conceptualized BiDil as a race specific therapy. As pointed out by Professor Kahn,
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In 1999, Cohn and others published a paper asserting that the HI
combinations worked better in blacks than ACE inhibitors.51 Spe-
cially, they concluded:
The H-I combination appears to be particularly effective in prolong-
ing survival in black patients and is as effective as enalapril in this
subgroup. In contrast, enalapril shows its more favorable effect in
the white population... [tihe consistency of observations of a racial
difference in response in V-HeFT I and V-HeFT II . . . lend
credence to the suggestion that therapy for heart failure might ap-
propriately be racially tailored.5 2
That same year Daniel Dries coauthored a study in the prestigious
New England Journal of Medicine suggesting that racial differences
exist in the natural progression of congestive heart failure. 53 The im-
plicit conclusion is that heart disease is a different disease in blacks
and whites and, therefore, it must be treated with different thera-
pies.54 This theory of biological difference is consistent with Jay
Cohn's claim that the black/white disparity in death rates from heart
failure is partly attributable to "a pathophysiology found in black pa-
tients that may involve Nitric Oxide (NO) insufficiency arising from
either reduced NO production, enhanced NO inactivation or both. '55
In 1999, NitroMed Inc., a Boston area biotech firm specializing in
the development and commercialization of nitric oxide enhanced
medicines, acquired the intellectual property rights to BiDil.56 Ni-
troMed announced its plans to amend the NDA to seek approval for
the use of BiDil to treat and prevent mortality associated with heart
failure in African-American patients.5 7 After a meeting in Washing-
Jay Cohn chose quite deliberately not to go into the racial data in his FDA presentation. Id. at
116.
51. Peter Carson et al., Racial Differences in Response to Therapy for Heart Failure: Analysis
of the Vasodilator-Heart Failure Trials, 5 J. CARDIAC FAILURE 178 (1999).
52. Id. at 182.
53. Daniel L. Dries et al., Racial Difference in the Outcome of Left Ventricular Dysfunction,
340 NEW ENG. J. MED. 609 (1999).
54. The idea that blacks and whites have a different course and progression of disease is not
new. Indeed, the scientific basis behind the infamous Tuskegee Syphilis Experiment was the
unproven theory that syphilis affected blacks and whites differently. Numerous black men in
Macon County, Alabama needlessly died and suffered as the United States Public Health Ser-
vice subjected them to unethical experiments without their consent. Nothing of scientific impor-
tance was gained from the study. See, e.g., JAMES JONES, BAD BLOOD (1993).
55. Press Release, NitroMed, NitroMed Initiates Confirmatory BiDil Trial in African Ameri-
can Heart Failure Patients (Mar. 17, 2001), available at http://www.nitromed.com/newsindex.html
(last visited Apr. 16, 2004).
56. Press Release, NitroMed, NitroMed Acquires BiDil New Drug Application for Treatment
of Congestive Heart Failure (Sept. 10, 1999), available at http://www.nitromed.com/new-
sindex.html (last visited Apr. 16, 2004).
57. Id.
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ton, the FDA approved the use of BiDil as a drug to treat heart failure
in African Americans, pending the successful results of a confirmatory
trial.58 That trial, A-HeFT, the African American Heart Failure Trial,
is currently underway.59
The FDA's tentative approval represents a significant expansion of
the potential BiDil market. NitroMed currently estimates that ap-
proximately 750,000 African Americans suffer from heart disease. 60
The implication is that all African Americans suffering from heart dis-
ease should be taking BiDil (because it is a different disease), not just
those who cannot tolerate or do not respond well to ACE inhibitors.
Without doubt, the huge commercial implications of the first ethnic
niche market allowed NitroMed to raise over $31.4 million from sev-
eral private venture capital firms to support the confirmatory trials.61
Recently, pharmaceutical giant Merck & Co., Inc. formed a multi-year
research collaboration with NitroMed, even though BiDil is the com-
pany's most advanced product to date. 62
V. A NEW THERAPY OR A NEW MARKET FOR AN
UNDERUSED DRUG?
BiDil started as a drug for use in the general population but has
emerged as a drug for use only in African Americans. A fundamental
question is whether significant scientific evidence demonstrates that
all African Americans with heart problems should take this drug, or
are NitroMed's claims merely a scheme to expand and exploit a po-
tentially lucrative market. As discussed below, substantial evidence
raises serious questions about the underpinnings of NitroMed's
claims.
First, the study authored by Peter Carson along with Jay Cohn,
claiming that blacks respond better to H/I than to ACE inhibitors,
retrospectively analyzed data from V-HeFT I and 11.63 It was not pro-
spectively designed to study racial differences in response to treat-
ment, rather, an existing and rather old data set was reanalyzed.
58. Press Release, NitroMed, supra note 6.
59. For a description of A-HeFT, see Clyde W. Yancy, Does Race Matter in Heart Failure?,
146 AM. HEART J. 203 (2003).
60. Kahn, supra note 37, at 107.
61. Press Release, NitroMed, NitroMed Completes $31.4 Million in Private Financing (June
14, 2001), available at http://www.nitromed.com/newsindex.html (last visited Apr. 16, 2004).
62. Press Release, Rho Ventures, NitroMed and Merck Form Strategic Collaboration: Com-
panies Enter Multi-Year Agreement to Research and Develop Nitric Oxide Based Medicines
(Jan. 7, 2003), available at http://www.rho.com/rho-ventures/media-center/investment-archive/
releases/nitromed_010703.html (last visited Apr. 16, 2004).
63. See Carson et al., supra note 51, at 178.
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There are well documented statistical problems involving randomiza-
tion and stratification by race in such retrospective studies. 64
Second, black participants had higher levels of comordid factors
such as diabetes and hypertension. 65 Essentially, the white and black
populations were not the same. Few doctors would use monotherapy
(a single drug) for cardiovascular disease in patients with concomitant
diabetes and hypertension. Therefore, this study may simply confirm
what we already know: use of a single ACE inhibitor at a standard
dose is not effective for patients who also have diabetes and hyperten-
sion, but is effective for patients without these conditions.
Third, the study purports to consider relevant nongenetic environ-
mental influences on the development and progression of heart fail-
ure, and includes two such factors-education and "financial distress
(yes vs. no) during the past twelve months. ''66 While education and
experience of financial distress are relevant factors to consider in ex-
amining nongenetic environmental influences, the implicit under-
standing is that they are exhaustive of all such relevant factors.
Vast medical and public health literature shows that a host of dele-
terious conditions accompany black status in the United States, in-
cluding differential exposures to environmental toxins, discrimination,
residential segregation, and differential political power, both in terms
of individual level of control and the allocation of resources.67 In-
deed, a Harvard study shows that the stress of experiencing racism
raises blood pressure.68 It is now well established that physiological
64. See, e.g., M. Packer et al., The Effect of Carvedilol on Morbidity and Mortality in Patients
with Chronic Heart Failure, 334 NEW ENG. J. MED 1349 (1996).
65. Carson et al., supra note 51, at 183.
66. Dries et al., supra note 53, at 612.
67. See Nancy Krieger et al., Racism, Sexism, and Social Class: Implications for Studies of
Health, Disease, and Well-Being, 9 AM J. PREVENTIVE MED. 82 (Supp. 1993); Thomas A.
LaVeist, The Political Empowerment and Health Status of African Americans: Mapping a New
Territory, 97 AM. J. Soc. 1080 (1992) (finding a statistically significant inverse association be-
tween black political power and black post neonatal mortality); Theodore J. Joyce et al., An
Assessment of the Benefits of Air Pollution Control: The Case of Infant Health, 25 J. URB. ECON.
32 (1989) (finding a link between environmental toxins and black infant mortality and
morbidity).
68. Nancy Krieger & Stephen Sidney, Racial Discrimination and Blood Pressure: The CAR-
DIA Study of Young Black and White Adults, 86 PUB. HEALTH REP. 1370 (1996). Kreiger and
coauthor Stephen Sidney asked 4,086 blacks and whites about their experiences with racial dis-
crimination. Black/white differences in blood pressure were substantially reduced by taking into
account reported experiences of racial discrimination and unfair treatment. Other studies lend
support to Krieger's view that internalized responses to racial discrimination may be associated
with elevated blood pressure. See, e.g., Vetta L. Sanders Thompson, Perceived Experiences of
Racism as Stressful Life Events, 32 COMMUNITY MENTAL HEALTH J. 223 (1996); Chery A. Arm-
stead et al., Relationship of Racial Stressors to Blood Pressure Responses and Anger Expression
in Black College Students, 8 HEALTH PSYCHOL. 541 (1989).
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processes respond to psychosocial stress.69 Therefore, the unmea-
sured variation in environmental exposures could account for the dif-
ferential response in hospitalization and survival, not differences in
drug metabolism.
Fourth, as fortune would have it, one of the strongest critiques has
come from one of the coauthors of the original study, Dr. Daniel
Dries. In 2002, Dries took issue with the earlier New England Journal
of Medicine piece arguing that the ACE inhibitor, enalapril, worked
equally well in blacks and whites:
Despite recent concerns that angiotensin-converting enzyme (ACE)
inhibitors may be less efficacious in black patients with [heart fail-
ure], the present study demonstrates that enalapril significantly re-
duced the risk of development of [heart failure] in both blacks and
whites .... The consistency of results in black and white subjects
strengthens the argument that ACE inhibitor-therapy should con-
tinue to be used in black patients with [heart failure]. 70
These findings are consistent with the recent African American Study
of Kidney Disease and Hypertension that demonstrated a benefit of
ACE inhibitor therapy in patients with renal disease. 71
Finally, NitroMed has relied heavily on the claim that African
Americans have twice the risk of dying from heart failure than
whites. 72 If this is true, then it is highly plausible that the difference is
due to genetic rather than environmental factors. This two-to-one dis-
parity has been floating around uncontested in the scientific literature
for decades. Dr. Jonathan Kahn of the University of Minnesota has
demonstrated conclusively that the NitroMed claim about the scope of
black and white differences is simply untrue. 73 Dr. Kahn traced the
citation sources back nearly two decades, and found that the differ-
ence between blacks and whites is actually 1.2 to 1.74 While there is a
difference, it is far less than the two-to-one ratio that would warrant
69. See, e.g., Bruce S. McEwen, Protective and Damaging Effects of Stress Mediators, 338 NEW
ENG. J. MED. 171 (1998).
70. Daniel Dries et al., Efficacy of Angiotensin-Converting Enzyme Inhibition in Reducing
Progression From Asymptomatic Left Ventricular Dysfunction to Symptomatic Heart Failure in
Black and White Patients, 40 J. AM. C. CARDIOLOGY 311, 314 (2002).
71. L.Y. Agoda, Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive
Nephrosclerosis: A Randomized Controlled Trial, 285 JAMA 2719 (2001). Other studies have
found the evidence too weak or inconclusive regarding the lack of ACE inhibitor benefit in
blacks. See, e.g., J.S. Kalus et al., Role of Race in Pharmacotherapy of Heart Failure, 36 ANNALS
OF PHARMACOTHERAPY 471 (2002); K.C. Ferdinand, Contemporary Treatment of Heart Failure:
Is There Adequate Evidence To Support a Unique Strategy for African Americans? Con Position,
4 CURRENT HYPERTENSION REP. 311 (2002).
72. Press Release, NitroMed, supra note 6.
73. Kahn, supra note 37, at 121-22.
74. Id.
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special trials for blacks. Thus, "substantial scaffolding of the BiDil
clinical trials is based upon incorrect statistical data on racial
disparities. '75
VI. RACE, DRUGS, AND COMMERCE-A
TROUBLING COMBINATION
Some doctors have already decided to no longer treat black patients
suffering from heart failure with ACE inhibitors. 76 This highlights the
potential harm to minority patients that will arise from the efforts to
market drugs along racial lines. The best or front-line therapy will
likely be replaced by a therapy that its promoters claim is more
effective.
In the case of ACE inhibitors, the Joint National Committee on
Prevention, Detection, Evaluation of High Blood Pressure (JNC VI)
concludes that "differences in antihypertensive efficacy between ACE
inhibitors and other agents can usually be overcome by higher doses"
or "dietary sodium reduction and diuretics. ' 77 As mentioned above, a
primary reason that blacks did not respond as well to ACE inhibitors
in Cohn's study was because they were sicker and, therefore, needed a
higher dosage. This strongly suggests that there is no clinical need for
BiDil.
Substituting BiDil for ACE inhibitors will likely lead to substandard
care. Recent findings show that ACE inhibitors have a significant
protective effect against stroke, diabetes, heart failure, and end-stage
kidney disease, independent of their blood pressure lowering proper-
ties. 78 The National Institutes of Health (NIH) stopped an ongoing
clinical trial comparing calcium blockers to ACE inhibitors after it be-
came clear that the ACE inhibitor significantly reduced mortality and
the need for dialysis. 79 NitroMed has made no claim that BiDil can
offer protection against organ damage or offer any secondary benefits.
75. Troy Duster, Medicine and People of Color: Unlikely Mix-Race, Biology and Drugs, S.F.
CHRON., Mar. 17, 2003, at B7.
76. Genes, Drugs and Race, supra note 31, at 239.
77. Joint Nat'l Comm. on Prevention, Detection, Evaluation & Treatment of High Blood
Pressure, The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation
and Treatment of High Blood Pressure, 157 ARCHIVES INTERNAL MED. 2413 (1997). The com-
mittee concluded that "ACE inhibition should be considered in all African-American patients
with hypertension, unless contraindicated, and not dismissed simply because of race or ethnic-
ity." Kenneth A. Jamerson, Rationale for Angiotensin II Receptor Blockers in Patients with Low-
Renin Hypertension, 36 AM. J. KIDNEY DISEASES 25 (2000 & Supp. 2000).
78. See, e.g., Jamerson, supra note 77.
79. NIH Modifies Trial as ACE Inhibitors Slow Renal Disease in African Americans, 56 GERI-
ATRICS, Jan. 2001, at 19.
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Indeed, no one knows what the long-term negative effects of the drug
will be.
African Americans are not a distinct genetic group and therefore do
not require a different and inferior drug for heart failure. Richard
Cooper, chairman of the preventive medicine and epidemiology de-
partment at Loyola University puts it this way: "I think it's bizarre,
marketing a drug to people who are black. The scientific evidence
supporting the notion that there's a differential response in race is
weak or nonexistent. '80
Other BiDils are sure to surface. Medical researchers are mining
through decades of old clinical trials data to find an overlooked differ-
ential racial response to drugs. 81 American drug giant Pfizer, Inc. is
particularly interested in hypertension-related genes in blacks.82
The combination of race, drugs, and corporate profits is eerie.
Fraud and genetic hucksterism are primary concerns. 83 Already, one
pharmaceutical company has misrepresented its data to help a plung-
ing stock. On February 24, 2003, the biotech company VaxGen, Inc.
publicly announced the results of the first ever phase III efficacy trial
of an HIV vaccine candidate. 84 The company reported the bad news
that there was little difference in the HIV infection rate between the
placebo group versus the participants who actually received the
shots.85 VaxGen shares sank almost 50%.86
When VaxGen broke the data down into racial groups, the company
proudly announced that the vaccine worked in blacks, causing infec-
tion rates to drop 78%.87 According to a market analyst, if the vac-
cine were approved only to treat blacks in the United States, the
potential market could be 7.6 million people and, assuming fifty dol-
lars per dose, that could generate revenue of approximately $2.3 bil-
lion over the next several years.88 VaxGen CEO Lance Gordon
80. Cha, supra note 19.
81. Holden, supra note 5, at 594.
82. Id. at 596.
83. The conjecture that possessing a financial interest increases research bias is empirically
testable. At least one study has demonstrated that clinical trials sponsored by pharmaceutical
companies were more likely to favor new drugs, an outcome beneficial to the sponsoring compa-
nies, than studies without corporate support. See Sheldon Krimsky, The Profit of Scientific Dis-
covery and Its Normative Implications, 75 CHI.-KENT L. REV. 15 (1999).
84. Press Release, VaxGen, VaxGen Announces Initial Results of Phase III AIDS Vaccine
Trial (Feb. 24, 2003), available at http://www.vaxgen.com/pressroom/index.html (last visited Apr.
16, 2004).
85. Id.
86. See Bernadette Tansey, Investors Drop VaxGen Stock: Brisbane Firm To Continue Work
on AIDS Vaccine, S.F. CHRON., Feb. 25, 2003, at B1.
87. Press Release, VaxGen, supra note 84.
88. Tansey, supra note 86.
[Vol. 53:11111124
2004] RACE AS A PROXY FOR DRUG RESPONSE
described the data on blacks as a "marvelous result" and said the com-
pany would still push for FDA approval of the vaccine for use with
high risk groups or populations in which the vaccine might be
effective. 89
Several AIDS advocacy groups demanded VaxGen's data and is-
sued statements outlining their concerns that the racial numbers were
wildly overstated, potentially as a deliberate face-saving and stock
price-saving strategy.90 VaxGen stood by its numbers. 91 Prompted by
advocacy groups, the NIH stepped in to resolve the issue. 92 After re-
viewing the data, the NIH reported that the finding of effectiveness in
blacks was "likely spurious. '93
Most, if not all, announcements of differential responses will likely
be spurious. While studies have identified a difference in the fre-
quency of drug metabolizing polymorphisms among blacks, these
studies are usually based on small sample sizes that make it impossible
to extrapolate the results to all African Americans. For instance, a
recent study claims that blacks metabolize nicotine at a slower rate
than whites.94 The study included only fifty-seven African Americans;
they were substantially more likely to smoke menthol brands than
whites. 95 The differences in metabolism were not impressive; there
was only an 8% difference in the variable of interest.96 The explicit
message, however, is that all blacks metabolize nicotine slowly.
VII. CONCLUDING THOUGHTS
The promise of pharmacogenomics is a future in which all medicine
is tailored to the individual. Drugs will be selected based not only on
the person's disease, but also on the likelihood to respond to the drug
and the person's chances of experiencing side effects. But selling
drugs is about markets. As Troy Duster points out, "[t]hese markets
are not about individual designer drugs, but about groups and popula-
89. AIDS Group: Vaccine Claims Misleading (Feb. 28, 2003), at http://www.vaccinationnews.
comfDailyNews/2003/February/AIDSGroup26.htm (last visited Apr. 23, 2004).
90. Id.
91. Press Release, VaxGen, VaxGen Issues Statement on Clinical Trial Data Analysis (Feb. 27,
2003), available at http://www.vaxgen.com/pressroom/index.html (last visited Apr. 16, 2004).
92. See Richard Jefferys, The Diabolic Science: VaxGen's Claims of Vaccine Efficacy Evanesce
in Autumn's Last Light, 10 TAGLINE 8 (2003), available at http://thebody.com/tag/oct03/vac-
cine.html (last visited Apr. 16, 2004).
93. Id.
94. Neal L. Benowitz et al., Ethnic Differences in N-Glucuronidation of Nicotine and Cotinine,
291 J. PHARMACOLOGY & EXPERIMENTAL THERAPEUTICS 1196 (1999).
95. Id. at 1197. Blacks cleared nicotine through the cotinine pathway at 14.8 mllmin/kg com-
pared to 17.7 ml/min/kg for whites. Id.
96. Id. at 1198.
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tion aggregates that become the target market. ' 97 Racial and ethnic
groups comprise large potential markets, and drug promoters are fi-
nancially motivated to search for racial differences in drug response.
Scientific objectivity can often be clouded by financial conflicts of
interest. In the mid-1980s, researchers found that clinical trials spon-
sored by pharmaceutical companies were much more likely to favor
new drugs (an outcome beneficial to sponsoring companies) than
studies not supported by companies. 98 Xigris is one example of how
selective use of data can show a positive effect of a drug when one
might not exist. Eli Lilly spent millions of dollars on this anti-sepsis
drug; there is no effective treatment for sepsis and the approval of this
drug would carry with it generous financial rewards. Halfway through
the study, however, Eli Lilly found no significant difference between
the placebo group and the group receiving the drug. After the re-
searchers excluded several categories of people (and the correspond-
ing data points), a significant positive result appeared. 99 This salient
point was not mentioned in the initial publication of the results but
surfaced during a meeting of an FDA approval committee that chas-
tised the study sponsors for concealing this fact.100
Our nation has a long and troubled history of mistreatment and op-
pression of racial groups in medicine based on incorrect theories and
misunderstandings about biological difference. 10 1 The results of
clinical trials on drug effectiveness are complex, hard to interpret, and,
therefore, prone to statistical sleight of hand. Our society must be
vigilant in insuring that pharmaceutical companies will not reap large
financial benefits from ethnic drugs at the expense of the health of
racial and ethnic minorities.
97. Duster, supra note 75.
98. See Krimsky, supra note 83, at 34.
99. Shares of Lilly Drop After Panel's Split on Sepsis Drug, N.Y. TIMES, Oct. 18, 2001, at C4.
100. In a split vote, the FDA Advisory panel was unable to recommend approval for Xigris
based on concerns that patient entry criteria changed halfway through the trial, which may have
exaggerated Xigris's efficacy results. Xigris gained FDA approval in November 2001. See Eli
Lilly's Xigris: Struggling to Overcome its Problems in the Sepsis Market, at http:/www.bioport
folio.com/news/datamonitor_29.htm (lasted visited on Apr. 16, 2004).
101. See Rene Bowser, Racial Profiling in Healthcare: An Institutional Analysis of Medical
Treatment Disparities, 7 MICH. J. RACE & L. 79 (2001).
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